Solara Active Pharma Sciences Ltd Q1 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/vk72ktur0sanjqyyx95878tr.pdf

Key Takeaways


Vizag Facility & Ibuprofen Opportunity

Purohit: "because of our existing set of customers actually, we were not able to fulfill those requirements because Vizag was not qualified. And because now we would be able to cater so in any case, customers are going to other competition now with the Vizag facility qualification also in place, we would cater to larger demand."

Cuddalore Regulatory Reset

Purohit: "we are expecting there are close to 13 approvals pending from the site. And these approvals will actually come because once the FDA does the inspection, they issue a zero 483 and after that, what happens is, it is from official action initiated the notification goes to no action initiated, after which we start getting approvals for product after product."

Margins & Mix


Product Pipeline & Backward Integration

Purohit: "we are close to 95 DMFs filed and I'm only talking about the US. And if you talk about the market extension, so there is still a lot of juice left in the company to capitalize on the existing set of products."

Management & Governance

Purohit: "we do expect no changes going on from here. And that is what we can vouch for because we have taken cognizance of the fact that a lot of changes have happened at the management level, which is not good for the company in the long run."

Balance Sheet & Cash Flow


Guidance & Commitments

CommitmentSpecificsTimeline
Gross margin recoveryReturn to 50% on a consistent level basisH2 FY24
Cuddalore product approvals~13 approvals to begin flowing post zero-483 status changeThis financial year (some sales)
Chairman appointmentNew Chairman identified and in placeNext 1–2 months
Rights issue termsDetails on structure and use of proceedsBy end-September (terms); 4–6 weeks (use of proceeds)
Debt reduction10% reduction in debtFY24
Vizag full operationsFacility fully operationalNext 18 months

Key Metrics

MetricQ1 FY24
Revenue growth5% YoY
Gross margin45.5%, up from 41% in Q1 FY23; down from 50% in Q4 FY23 due to product and geography mix
EBITDA₹20 cr, 23% growth YoY before forex; 11% growth after forex
Regulated market sales mix68%, down from 72% QoQ
Gross debt reduction₹14 cr reduction in Q1
Current assets reduction₹34 cr reduction in Q1, primarily due to improved collections
Order bookDoubled from Q1 FY23
CRAMS revenue share5% of revenue
US DMFs filed~95 DMFs filed
Vizag utilizationDoubled
Vizag full-operations timeline~18 months
FY24 debt reduction target10% reduction
Rights issue completionBy end of September
Cuddalore facility US FDA inspection outcomeZero 483 inspectional observations
Market extensions in Q18 market extensions for 7 existing products